

Curriculum Vitae

Personal information **Martijn van Gils**

Work experience

1. Employer: Medical Evaluation Board
 - Start date: 03-2019
 - End date:
 - Position: Senior Clinical Assessor
 - Country: Netherlands
2. Employer: Medical Evaluation Board
 - Start date: 09-2016
 - End date: 02-2019
 - Position: Clinical Assessor
 - Country: Netherlands
3. Employer: Catharina Hospital Eindhoven
 - Start date: 05-2015
 - End date: 06-2016
 - Position: Urologist
 - Country: Netherlands
4. Employer: Máxima Medical Centre Veldhoven
 - Start date: 09-2014
 - End date: 04-2015
 - Position: Urologist
 - Country: Netherlands
5. Employer: Radboud University Nijmegen Medical Centre
 - Start date: 01-2014
 - End date: 08-2014
 - Position: Laparoscopic urology fellow
 - Country: Netherlands
6. Employer: Meander Medical Centre Amersfoort
 - Start date: 01-2013
 - End date: 12-2013
 - Position: Laparoscopic urology fellow
 - Country: Netherlands

Education and training

1. Subject: Residency in urology
 - Start date: 2007
 - End date: 2012
 - Organisation: Radboud University Nijmegen Medical Centre
 - Country: Netherlands
2. Subject: Doctorate in Medical Sciences (PhD)
 - Start date: 2004
 - End date: 2009
 - Organisation: Radboud University Nijmegen
 - Country: Netherlands
3. Subject: Medicine (MD)
 - Start date: 1997
 - End date: 2004
 - Organisation: Utrecht University
 - Country: Netherlands

Additional information

Publications

Weijers Y, van Gils MPMQ, Langenhuijsen JF, Fransisca EAE, d'Ancona FCH. Case report. Pubic osteomyelitis, a rare but disabling complication after GreenLight Laser Therapy photoselective vaporization of the prostate. Tijdschr Urol 2015;5(5):135_8

van Gils MPMQ, Weijerman PC. An extreme case of benign prostatic hyperplasia. Ned Tijdschr Urol 2010;18(8):222_4

Ploussard G, Haese A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Bastien L, Abbou C_C, Remzi M, Tinzi M, Feyerabend S, Stillebroer AB, van Gils MPMQ, Schalken JA, de la Taille A. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free to total prostate specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 2010;106(8):1143_7

Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Abbou C_C, Stillebroer AB, van Gils MPMQ, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56(4):659_68. Eur Urol 2010;57(1):e2_3

Hessels D, van Gils MPMQ, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, Schalken JA. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate

2010;70(1):10_6

van Gils MPMQ, Hessels D, Peelen WP, Vergunst H, Mulders PFA, Schalken JA. Preliminary evaluation of the effect of dutasteride on PCA3 in post_DRE urine sediments; a randomized, open_label, parallel_group pilot study. Prostate 2009;69(15):1624_34

Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Abbou C_C, Stillebroer AB, van Gils MPMQ, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. Prostate Cancer Gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56(4):659_68

Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, Huland H, Abbou C_C, Remzi M, Tinzi M, Feyeraend S, Stillebroer AB, van Gils MPMQ, Schalken JA. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54(5):1081_1088

van Gils MPMQ, Hessels D, Hulsbergen _ van de Kaa CA, Witjes JA, Jansen CFJ, Mulders PFA, Rittenhouse HG, Schalken JA. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68(11):1215_22

van Gils MPMQ, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PFA, Rittenhouse HG, Schalken JA. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007;67(8):881_7

van Gils MPMQ, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, Witjes JA, Cornel EB, Karthaus HFM, Smits GAHJ, Dijkman GA, Mulders PFA, Schalken JA. Validation of the PCA3 urine test in a multicenter study in the Netherlands. Ned Tijdschr Urol 2007;15(2):48_53

van Gils MPMQ & Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, Witjes JA, Cornel EB, Karthaus HFM, Smits GAHJ, Dijkman GA, Mulders PFA, Schalken JA. The time resolved fluorescence_based PCA3 test on urinary sediments after extended digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13(3):939_43

van Gils MPMQ, Mulders PFA. The standard of the Dutch College of General Practitioners on micturition disorder in elderly men. Ned Tijdschr Urol 2005;13(8):213_4

van Gils MPMQ, Stenman UH, Schalken JA, Schröder FH, Luiden TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KSI, Bischoff R, Takalo H, Nilsson O, Mulders PFA, Bangma CH. Innovations in serum and urine markers in prostate cancer; Current European research in the P_Mark project. Eur Urol 2005;48(6):1031_41

van Gils MPMQ, Mulders PFA. The practice guideline 'Lower urinary_tract symptoms in middle_aged and elderly men' (second revision) from the Dutch College of General Practitioners; a response from the perspective of urology. Ned Tijdschr Geneeskde 2005;149(28):1551_2

van Gils MPMQ, Mulders PFA. Medical therapy in symptomatic benign prostatic hyperplasia. Ned Tijdschr Urol 2005;13(4):101_6

Projects

Memberships

Other Relevant Information